144 related articles for article (PubMed ID: 34740722)
1. Dual cancer stem cell manipulation to enhance phototherapy against tumor progression and metastasis.
Shang Q; Zhou S; Zhou Z; Jiang Y; Luan Y
J Control Release; 2021 Dec; 340():282-291. PubMed ID: 34740722
[TBL] [Abstract][Full Text] [Related]
2. Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy.
Paholak HJ; Stevers NO; Chen H; Burnett JP; He M; Korkaya H; McDermott SP; Deol Y; Clouthier SG; Luther T; Li Q; Wicha MS; Sun D
Biomaterials; 2016 Oct; 104():145-57. PubMed ID: 27450902
[TBL] [Abstract][Full Text] [Related]
3. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
[TBL] [Abstract][Full Text] [Related]
4. SURVIVIN as a marker for quiescent-breast cancer stem cells-An intermediate, adherent, pre-requisite phase of breast cancer metastasis.
Siddharth S; Das S; Nayak A; Kundu CN
Clin Exp Metastasis; 2016 Oct; 33(7):661-75. PubMed ID: 27411340
[TBL] [Abstract][Full Text] [Related]
5. Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.
Yang X; Shi X; Ji J; Zhai G
Drug Deliv; 2018 Nov; 25(1):780-796. PubMed ID: 29542333
[TBL] [Abstract][Full Text] [Related]
6. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
7. Engineering of a dual-modal phototherapeutic nanoplatform for single NIR laser-triggered tumor therapy.
Zhang M; Qin X; Xu W; Wang Y; Song Y; Garg S; Luan Y
J Colloid Interface Sci; 2021 Jul; 594():493-501. PubMed ID: 33774405
[TBL] [Abstract][Full Text] [Related]
8. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
9. Targeting Breast Cancer Stem Cells.
Zhang L; Chen W; Liu S; Chen C
Int J Biol Sci; 2023; 19(2):552-570. PubMed ID: 36632469
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
11. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy.
Burke AR; Singh RN; Carroll DL; Wood JC; D'Agostino RB; Ajayan PM; Torti FM; Torti SV
Biomaterials; 2012 Apr; 33(10):2961-70. PubMed ID: 22245557
[TBL] [Abstract][Full Text] [Related]
12. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Targeting of Differentiated Breast Cancer Cells and Breast Cancer Stem Cells by Combination of Docetaxel- and Sulforaphane-Loaded Self-Assembled Poly(D, L-lactide-co-glycolide)/Hyaluronic Acid Block Copolymer-Based Nanoparticles.
Huang J; Tao C; Yu Y; Yu F; Zhang H; Gao J; Wang D; Chen Y; Gao J; Zhang G; Zhou G; Liu J; Sun Z; Sun D; Zou H; Xu H; Lu Y; Zhong Y
J Biomed Nanotechnol; 2016 Jul; 12(7):1463-77. PubMed ID: 29337484
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts.
Liu S; Cong Y; Wang D; Sun Y; Deng L; Liu Y; Martin-Trevino R; Shang L; McDermott SP; Landis MD; Hong S; Adams A; D'Angelo R; Ginestier C; Charafe-Jauffret E; Clouthier SG; Birnbaum D; Wong ST; Zhan M; Chang JC; Wicha MS
Stem Cell Reports; 2014 Jan; 2(1):78-91. PubMed ID: 24511467
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance.
Mallini P; Lennard T; Kirby J; Meeson A
Cancer Treat Rev; 2014 Apr; 40(3):341-8. PubMed ID: 24090504
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer stem cells: Multiple capacities in tumor metastasis.
Geng SQ; Alexandrou AT; Li JJ
Cancer Lett; 2014 Jul; 349(1):1-7. PubMed ID: 24727284
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity and Plasticity of Breast Cancer Stem Cells.
Sousa B; Ribeiro AS; Paredes J
Adv Exp Med Biol; 2019; 1139():83-103. PubMed ID: 31134496
[TBL] [Abstract][Full Text] [Related]
18. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium.
Feng ZM; Qiu J; Chen XW; Liao RX; Liao XY; Zhang LP; Chen X; Li Y; Chen ZT; Sun JG
BMC Cancer; 2015 Sep; 15():645. PubMed ID: 26400441
[TBL] [Abstract][Full Text] [Related]
19. Signaling pathways governing breast cancer stem cells behavior.
Song K; Farzaneh M
Stem Cell Res Ther; 2021 Apr; 12(1):245. PubMed ID: 33863385
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound targeted microbubble destruction-mediated SOCS3 attenuates biological characteristics and epithelial-mesenchymal transition (EMT) of breast cancer stem cells.
Tang X; Hao N; Zhou Y; Liu Y
Bioengineered; 2022 Feb; 13(2):3896-3910. PubMed ID: 35109743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
